The official website of the China Drug Clinical Trial Registration and Information Disclosure Platform recently announced that GlaxoSmithKline (GSK) has initiated a Phase 2 single-arm clinical study of dostarlimab in China for untreated dMMR/MSI-H locally advanced colorectal cancer patients.
According to the latest announcement on the official website of the China Drug Clinical Trial Registration and Information Disclosure Platform, GlaxoSmithKline (GSK.US) has initiated a Phase 2 single-arm clinical study of dostarlimab in China for untreated dMMR/MSI-H locally advanced colorectal cancer patients.
Public information shows that dostarlimab is an anti-PD-1 monoclonal antibody, which was clinically approved in China for the first time in July this year. GSK recently released the latest long-term data from a Phase 2 clinical trial of first-line treatment for dMMR/MSI-H locally advanced colorectal cancer. In this study, patients receiving the investigational drug showed a clinical complete response rate (cCR) of 100%. The Phase 2 clinical study launched by the researchers in China specifically targeted this indication.
Screenshot source: China Drug Clinical Trial Registration and Information Disclosure Platform official website
Dostarlimab is a PD-1 blocking antibody that can bind to the PD-1 receptor and block its interaction with the PD-1 ligands PD-L1 and PD-L2. The product has been approved by the FDA for multiple indications, including dMMR advanced or recurrent endometrial cancer, dMMR or MSI-H primary advanced or recurrent endometrial cancer, and dMMR recurrent or advanced solid tumors. In addition, GSK is continuing to explore the therapeutic potential of this drug in multiple Phase 3 clinical trials.